Many consumer groups feel that the Country A drug approval process is too easy and, as a result, too many drugs are approved that are later found to be unsafe. On the other hand, a number of industry lobbyists have pushed for a morelenient approval process so that pharmaceutical companies can get new drugs approved more easily and quickly. Consider a null hypothesis that a new, unapproved drug is unsafe and an alternative hypothesis that a new, unapproved drug issafe. Complete parts (a) through (d) below......a. Explain the risks of committing a Type I or Type Il error. Choose the correct answer below.A. A Type l error would be incorrectly approving a safe drug. A Type Il error would be incorrectly failing to approve an unsafe drug.B. A Type l error would be incorrectly failing to approve an unsafe drug. A Type Il error would be incorrectly approving a safe drug.C. A Type I error would be incorrectly approving an unsafe drug. A Type Il error would be incorrectly failing to approve a safe drug.CD. A Type I error would be incorrectly failing to approve a safe drug. A Type II error would be incorrectly approving an unsafe drug.b. Which type of error are the consumer groups trying to avoid? Explain. Choose the correct answer below.A. The consumer groups are trying to avoid a Type I error because they think that too many unsafe drugs are approved.B. The consumer groups are trying to avoid a Type Il error because they think that too many unsafe drugs are approved.C. The consumer groups are trying to avoid a Type I error because they think that too many safe drugs are unapproved.D. The consumer groups are trying to avoid a Type Il error because they think that too many safe drugs are unapproved.

The following are some test hypotheses:The null hypothesis is:H0: An unapproved new medicine is…

Many consumer groups feel that the Country A drug approval process is too easy and, as a result, too many drugs are approved that are later found to be unsafe. On the other hand, a number of industry lobbyists have pushed for a more lenient approval process so that pharmaceutical companies can get new drugs approved more easily and quickly. Consider a null hypothesis that a new, unapproved drug is unsafe and an alternative hypothesis that a new, unapproved drug is safe. Complete parts (a) through (d) below. ... a. Explain the risks of committing a Type I or Type error. Choose the correct answer below. O A. A Type I error would be incorrectly approving a safe drug. A Type Il error would be incorrectly failing to approve an unsafe drug. O B. A Type l error would be incorrectly failing to approve an unsafe drug. A Type Il error would be incorrectly approving a safe drug. C. A Type l error would be incorrectly approving an unsafe drug. A Type Il error would be incorrectly failing to approve a safe drug. D. A Type l error would be incorrectly failing to approve a safe drug. A Type Il error would be incorrectly approving an unsafe drug. b. Which type of error are the consumer groups trying to avoid? Explain. Choose the correct answer below. O A. The consumer groups are trying to avoid a Type I error because they think that too many unsafe drugs are approved. O B. The consumer groups are trying to avoid a Type Il error because they think that too many unsafe drugs are approved. OC. The consumer groups are trying to avoid a Type I error because they think that too many safe drugs are unapproved. O D. The consumer groups are trving to avoid a Type |l error because they think that too many safe drugs are unapproved.

2nd Edition

ISBN:9780321964038

Author:GREENWELL, Raymond N., RITCHEY, Nathan P., Lial, Margaret L.

Publisher:GREENWELL, Raymond N., RITCHEY, Nathan P., Lial, Margaret L.

Chapter10: Matrices

Section10.EA: Extended Application Contagion

Problem 2EA